title: Cytotoxic T cell activity against the peptide, AYRARALEL, from Yo protein of patients with the HLA A24 or B27 supertype and paraneoplastic cerebellar degeneration.
abstract: OBJECTIVE
  To determine a peptide that reacts with cytotoxic T cells (CTL) of patients with paraneoplastic cerebellar degeneration and anti-Yo antibodies with either HLA A24 or B27 supertype.
  
  
  METHODS
  We studied CTL activity of four patients, three were HLA A24-positive and one did not have HLA A24 but had B27 supertype. After an incubation of mononuclear cells with or without peptide and IL-2, CD8-rich fraction was prepared by treatment with Magnetic Cell Sorting system (MACS) twice. CTL activity was calculated by 51Cr release from transfectant, C1RA*2402 as target cells. The peptide-binding assay was examined by flow cytometry.
  
  
  RESULTS
  Two of three HLA A 24-positive patients demonstrated CTL activity against the Yo peptide, AYRARALEL. CTL activity was found to be 19.5% and 11.7% at the effector/target (E/T) ratio of 23:1 and 11:1, respectively. A patient who did not have HLA A24 but had A2 and B27 supertype possessed a CTL activity of 19.4% with 15:1 as E/T ratio. The peptide could bind to HLA A*2402 molecules but not to A*0201.
  
  
  CONCLUSIONS
  We showed CTL activity in two of three Japanese patients with HLA A24 by using HLA A*2402 transfectant cells as the target. In addition, we identified the first Japanese patient who had B27 supertype, and suggested that the same peptide, AYRARALEL, could be recognized by CTL in this patient.
authors.affiliation: Department of Neurology, National West Niigata Central Hospital, 950-2085, Niigata, Japan. masami@masa.go.jp
authors.forename: M
authors.initials: M
authors.lastname: Tanaka
authors.forename: K
authors.initials: K
authors.lastname: Tanaka
authors.forename: S
authors.initials: S
authors.lastname: Tsuji
authors.forename: A
authors.initials: A
authors.lastname: Kawata
authors.forename: S
authors.initials: S
authors.lastname: Kojima
authors.forename: T
authors.initials: T
authors.lastname: Kurokawa
authors.forename: J
authors.initials: J
authors.lastname: Kira
authors.forename: M
authors.initials: M
authors.lastname: Takiguchi
mesh_terms: D001324:Autoantigens; D002526:Cerebellar Diseases / Q000276:immunology*; D004268:DNA-Binding Proteins / Q000276:immunology*; D000939:Epitopes; D015234:HLA-A Antigens / Q000032:analysis*; D059871:HLA-A24 Antigen; D015796:HLA-B27 Antigen / Q000032:analysis*; D006801:Humans; D009363:Neoplasm Proteins / Q000276:immunology*; D009410:Nerve Degeneration / Q000276:immunology*; D009419:Nerve Tissue Proteins; D010257:Paraneoplastic Syndromes / Q000276:immunology*; D010446:Peptide Fragments / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000502:physiology*
chemical_list: D001324:Autoantigens; C063762:CDR1 protein, human; C095184:CDR2 protein, human; D004268:DNA-Binding Proteins; D000939:Epitopes; D015234:HLA-A Antigens; D059871:HLA-A24 Antigen; D015796:HLA-B27 Antigen; D009363:Neoplasm Proteins; D009419:Nerve Tissue Proteins; D010446:Peptide Fragments